An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL) Meeting Abstract

  


Authors: Younes, A.; Salles, G.; Martinelli, G.; Bociek, R. G.; Barrigon, D. C.; Barca, E. G.; Turgut, M.; Gerecitano, J. F.; Herbst, F.; Williams, L.; Mukherjee, N.; Tavorath, R.; Kim, W. S.
Abstract Title: An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL)
Meeting Title: 57th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 126
Issue: 23
Meeting Dates: 2015 Dec 5-8
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2015-12-03
Language: English
ACCESSION: WOS:000368019004293
PROVIDER: wos
DOI: 10.1182/blood.V126.23.1493.1493
Notes: Meeting Abstract: 1493 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. John Frank Gerecitano
    153 Gerecitano
  2. Anas Younes
    319 Younes
Related MSK Work